Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2015

View Archived Issues

Atossa acquires license to afimoxifene gel for breast hyperplasia

Sanofi explores TrpC6 inhibition with SAR-7334

Sciex and National University of Singapore sign memorandum of understanding

Ablynx and Genzyme to investigate Nanobodies for multiple sclerosis

R-Tech Ueno and Hokkaido University to investigate RTU-1096 for ophthalmic indications

MSKCC starts phase I trial of mesothelin-targeted T-cell therapy in pleural tumors

Genmab and BioNTech form immuno-oncology collaboration

OncoSec funds preclinical research into ImmunoPulse IL-12 in HPV-related cancer

Broad Institute to study cancer drug resistance

Takeda Pharmaceutical reviews milestones of fourth quarter of fiscal 2014

Erythropoietin analogue ARA-290 enhances experimental pancreatic islet transplantation

Sirona discovers antioxidant properties of lead antiaging compound

In vitro and in vivo activity of VT-1161 against Rhizopus oryzae

PGN-9856-I reduces IOP in animal model

DNAtrix to use Alcyone's AMC platform for intratumoral delivery of DNX-2401

ARNO Therapeutics reveals broad-spectrum host-directed antiviral agent

Idera Pharmaceuticals' IMO-9200 tested in preclinical studies for IBD

French and Polish researchers patent PR3 inhibitors

HanAll BioPharma presents new antitumor biguanides

Boehringer Ingelheim develops AMPK activators

Topline results from phase II trial of GEN-003 for genital herpes

Acid pump antagonist CJ-12420 begins phase III trial in Korea

Topline results released from phase III studies of sarilumab for rheumatoid arthritis

AbGenomics starts phase Ib/IIa trial of neihulizumab in acute GvHD

Sarepta to begin rolling NDA submission for eteplirsen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...